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Vaginal mesh vs. native tissue repairs for prolapse: FDA update and 
recent evidence 
 
Catherine S. Bradley, MD, MSCE1 
 
In 2010, 300,000 surgeries were 
performed in the U.S. for pelvic organ 
prolapse (POP), and 100,000 of those 
involved the placement of surgical 
mesh. The use of mesh in abdominal 
surgeries for POP has been described 
for over 50 years, but the first surgical 
mesh product specifically for POP was 
approved by the FDA in 2002. Over the 
last decade, transvaginal mesh POP 
surgeries have become more common, 
and mesh “kits” have been approved 
and are increasingly used for 
transvaginal POP repair, but clinical trial 
evidence of their safety and 
effectiveness has lagged behind rapid 
adoption into practice.  
  
Mesh use has been advocated in part 
because of low success rates after 
traditional vaginal POP repairs. 
However, increasing research suggests 
previously recommended anatomic 
outcomes for prolapse surgery are too 
strict, as these definitions would classify 
many “normal” women as having 
prolapse. Furthermore, evidence shows 
that subjective symptom outcomes that 
include an absence of bulge symptoms 
correlate best with patients’ impression 
of improvement, while outcomes based 
solely on anatomic criteria do not. 
Recent recommendations are that POP 
surgery definitions of success should 
include the absence of bulge symptoms 
in addition to anatomic criteria. 
Reanalysis of trial data using such 
outcomes demonstrate high success 
rates (>80%) for traditional vaginal 
repairs (e.g. anterior colporrhaphy), in 
contrast to lower success rates based 
on strict anatomic criteria alone. 
  
In July 2011 the FDA published an 
“Update on Safety and Effectiveness for 
Transvaginal Placement of Surgical 
Mesh for Pelvic Organ Prolapse,” 
summarizing recent Manufacturer and 
User Device Experience (MAUDE) 
database reports related to transvaginal 
mesh repairs and results of a systematic 
literature review. From 2008-2010, 1503 
MAUDE reports associated with mesh 
for POP were entered, a 5-fold increase 
compared to the previous 3-year period. 
Complications frequently reported 
included mesh erosion, 
pain/dyspareunia, infection, urinary 
problems, bleeding and organ 
perforation. A systematic review of over 
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11,000 women from 110 studies of 
transvaginal mesh repairs found then 
overall mesh erosion incidence was 
10.3%, and more than half of cases 
required surgical intervention.  
 
The FDA also reviewed evidence for the 
efficacy of transvaginal mesh repairs, 
concluding that clinical benefit for apical 
and posterior mesh repairs over 
traditional repairs has not been 
demonstrated. Anterior vaginal mesh 
repair does appear to confer an 
anatomic benefit compared to non-mesh 
procedures, but this may not result in 
better outcomes. Thus, the current 
literature suggests that transvaginal 
mesh POP repairs expose patients to 
additional risks and do not conclusively 
improve overall outcomes compared to 
traditional repairs. The FDA is now 
considering regulatory changes to the 
approval process for transvaginal mesh 
devices, which might include an 
increase in risk classification, which 
would require manufacturers to present 
clinical data before approval, as well as 
expanded post-market monitoring or 
surveillance requirements for currently-
approved devices.  
  
In this uncertain climate surrounding the 
use of transvaginal mesh, clinicians 
should be familiar with the available 
evidence, make informed decisions 
about recommended procedures and 
tailor choice of procedure to each 
patient. Sufficient surgeon training and 
volume in mesh POP surgeries are 
important to optimize outcomes. Most 
importantly, surgeons must ensure that 
patients understand the risks and 
benefits related to mesh through a 
thorough and well-documented informed 
consent process.  
 
